Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chronic lymphocytic leukemia (rrCLL), multiple myeloma (rrMM), or diffuse large B-cell lymphoma (rrDLBCL).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Relapsed or refractory chronic lymphocytic leukemia (rrCLL) participants:
Relapsed or refractory multiple myelolma (rrMM) participants:
Diffuse large B-cell lymphoma (rrDLBCL) participants:
Exclusion criteria
Relapsed or refractory chronic lymphocytic leukemia (rrCLL) participants:
Relapsed or refractory multiple myelolma (rrMM) participants:
Diffuse large B-cell lymphoma (rrDLBCL) participants:
Primary purpose
Allocation
Interventional model
Masking
75 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal